Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer

HER2‐targeted therapy, especially the anti‐HER2 antibody trastuzumab, is standard for HER2‐positive breast cancer; however, its efficacy is limited in a subpopulation of patients. HER3 ligand (heregulin)‐dependent HER2‐HER3 interactions play a critical role in the evasion of apoptosis and are theref...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Satomi, Yonesaka, Kimio, Tanizaki, Junko, Nonagase, Yoshikane, Takegawa, Naoki, Haratani, Koji, Kawakami, Hisato, Hayashi, Hidetoshi, Takeda, Masayuki, Tsurutani, Junji, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434202/
https://www.ncbi.nlm.nih.gov/pubmed/30701699
http://dx.doi.org/10.1002/cam4.1995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434202/
https://www.ncbi.nlm.nih.gov/pubmed/30701699
http://dx.doi.org/10.1002/cam4.1995

Ejemplares similares